DNA Link, Inc. announced that it expects to receive KRW 8 billion in funding from Shinhan Capital Co., Ltd.
March 06, 2019
Share
DNA Link, Inc. (KOSDAQ:A127120) announced a private placement of KRW 8,000,000,000 domestic weapon unregistered coupon unguaranteed private convertible bonds in round 8 on March 7, 2019. The company will issue bonds for proceeds of KRW 2,300,000,000 to trust dealer Korea Securities Finance Corporation the corporation, KRW 1,700,000,000 to trust dealer Yen H investments securities corporation, KRW 2,000,000,000 to trust dealer KB securities corporation, KRW 600,000,000 to trust dealer Yen H investments securities corporation, KRW 200,000,000 to trust dealer Shinhan Investment Corp. corporation, KRW 200,000,000 to trust dealer Korea Investment & Securities Co., Ltd. Corporation, and KRW 1,000,000,000 to Shinhan Capital Co., Ltd. The bond carry coupon rate of 0% and yield to maturity of 2.5%. The bonds will mature on March 11, 2022. The bonds are payable on March 11, 2019. The bonds are 100% convertible into 1,598,401 shares at a conversion price of KRW 5,005 per share. The conversion period starts from March 11, 2020 and ends on February 11, 2022. The transaction has been approved by the board of directors of the company.
DNA LINK, INC. is a Korea-based company engaged in the genetics research business. The Company provides genome biomarkers excavation products through integrated genomic analysis and integrated clinical information analysis including high-quality data products according to genomic analysis, interpretation of analysis results, and technologies of molecular diagnostic kit production under the brand name of enhanced genome integration system (EGIS). The Company also provides personal genome analysis service products under the brand name of deoxyribonucleic acid personalized services (DNAGPS).
DNA LINK, INC. 
